EZH2 and mantle cell lymphoma: In MCL with aggressive histologic variants, patients with EZH2+ MCL had a poorer outcome than patients with EZH2-negative MCL (median OS, 3.7 and 7.9 years, respectively, p = 0.0458) (Fig. 3D).